AgeX Therapeutics Inc (AGE)

[saxonia40271]

The price explosion in October 2020, was baseless, and a complete misunderstanding, possibly deliberately circulated by someone on social media. I'm not sure, where it started, only that it started after a meaningless form SC 13D/A. It was a simple formality. Juvenescence already owned almost half of AgeX, before it was even listed. But I share the bullish outlook, even though I don't expect anyone, to have to pay a fortune for longevity. The therapeutics might be obtained by governments around the world, and given to the people, freely. That doesn't make it any less interesting. The actual longevity technology might become independent. It's already in a subsidiary. If you believe, this will all work out, then the potential might be almost limitless, but it could take some patience. And of course, all early stage biotechs are high-risk, but this one definitely has the opportunities to match.

[vinaynankani]

I’ve followed the longevity sector for a long time, and looked at this little stock - it blew up last year, wondering if it could again?

These guys have published some research on them, setting a target of $3.1. Is it legit?

Here’s their report: https://internetbullreport.com/agex-novel-therapeutics-targeting-human-aging/

[saxonia40271]

Your text is better than most. Not to worry, all good. Thanks for your kind words. OCX has produced a significant disappointment, back in 2019. The stock has recovered, but I'm uncertain about their future. As for LCTX, they've done quite nicely, in recent history. The stock has done well, and I think, it still has potential. Their top-of-the-line product shows great promise in regenerating the eye, and restore vision. They've already treated a patient in Israel, on a compassionate-use basis. The trials are going well. I'd be pleased, if you got something out of this, for your personal medical benefit. The field is making rapid progress. I think, both AgeX and LCTX are good choices. It's difficult to predict, how far and how fast the stock will come. Things can often change, very rapidly. But in both cases, I'm optimistic about their respective projects. Good luck to you!

[Cincinnatus]

I appreciate your detailed response. It was way more than I expected. Thank you.

I go back to the BTX time and an introduction to the company from John Mauldin and a biotech consultant named Cox. I do not have a strong scientific background so I just sort of lurked on the wall, waiting for the communication crumbs that drop now and then. I'm 85 years old and have had some severe medical problems that last 2 years, but am trying to get back in action a litttle recently.

With limited knowledge and time, I'm not going to try for more depth in you detailed scientific swamp. I'll wait and observe.

One question more. I haven't paid any attention to OCX, but it seems that LCTX has some irons in the fire that might provoke some investment possibilitieis ...but again how soon??? Do you think that any of the three LCTX strands could produce any revenue in the next three to rour years.

I'm legally blind using special computer programing from the VA so if I've made typing errors, please excuse.

[saxonia40271]

They have more irons in the fire than ever before. There's the pending merger with LyGenesis, that will instantly turn them into a phase 2a company. It's also possible that Morphoceuticals, Inc. will join them, somewhere down the road. AgeX's most exciting technology, that's been transferred to their subsidiary Reverse Bioengineering, is likely to become autonomous, which was probably the plan, all along. One reason is that its success could undermine much of the other projects.

The AgeX staff has recently granted themselves a significant number of call options, with a term of 10 years. Juvenescence has three main shareholders, who presently own 51% of the company. AgeX in turn belongs to Juvenescence, by currently over 50%. AgeX's pre-merger shareholders are supposed to retain an 80% "economic interest" in Reverse Bio, which is likely their most exciting project. On behalf of the three main investors, co-founder Jim Mellon just recently affirmed that none of them will be selling any shares. From the way it sounded, he probably meant, they won't be selling in years, maybe not even in decades. They intend to see the mission through.

Unfortunately, as much as they might be one of the most exciting bets of all time, they're also not exactly known for being communicative, for a number of reasons. You might almost say, they operate in some sort of indefinite stealth mode, with a number of issues to work out. But the veil will lifted, eventually. As much as this might not be very popular with the troops, this company, if successful, could be one of the best examples of the stock market, being about reallocating money, from the impatient to the patient. Your call.

[Cincinnatus]

Any information about Juvenescence and some actual revemue efforts in the next year? Or do we just remain a science research center with no hope for a stock that might have some market value in the next few years?

With a $50M package for them in 2019, might one hope for some actual plans, timelines, goals, etc. being communicated to shareholders as if this was an actual investment vehicle rather than the science project that seems to be the message so far.

[saxonia40271]

AgeX to be added to the Russell Microcap Index.

LCTX is also added to the Microcap and the Russell 3000 Index.

https://content.ftserussell.com/sites/default/files/russell_microcap_additions_-_2021.pdf

[saxonia40271]

Study shows, how to boost muscle regeneration and rebuild tissue.

https://www.nature.com/articles/s41467-021-23353-z.pdf

https://www.salk.edu/news-release/new-study-shows-how-to-boost-muscle-regeneration-and-rebuild-tissue/

[saxonia40271]

Cell Senescence, Telomerase, and Senolytic Therapy

http://lidsen.com/journals/geriatrics/geriatrics-03-01-034

[saxonia40271]

Telomerase and cancer: A complex relationship

http://www.lidsen.com/journals/geriatrics/geriatrics-05-01-156

[saxonia40271]

A unified model of dementias and age-related neurodegeneration

https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12012

[saxonia40271]

A podcast with David Sinclair and Joanna Masel

https://munkdebates.com/podcast/ageing

[saxonia40271]

We can only guess, how much pressure must be in the boiler, by now. At the same time, their communications morale has dropped to an all-time low. They might eventually walk in on us, with lock, stock and barrel at once. We know, they‘re working to get RB underway, and to make a concrete proposal, regarding the merger. That should make for plenty of action and new prospects. If the stock actually goes lower still, it might be a very brief dip. It's grotesque already. All of this defies belief.

[saxonia40271]

300 Million Euros for rejuvenation startups.

This guy is a German internet entrepreneur, founder of the Forever Healthy Foundation that hosts the Undoing Aging Conference, and he was involved in the seed funding of AgeX.

https://www.forever-healthy.org/news

[Cincinnatus]

What happened to the big plans with Juvenesence? I thought the billionaire was going to take over the biotech world. LCTX seems to have something resembling a weak pulse, but AGE seems to be a moribund research project.

[saxonia40271]

No Time to Age: Uncoupling Aging from Chronological Time

https://www.preprints.org/manuscript/202104.0384/v1/download

[saxonia40271]

This analysis may epically underestimate the company‘s potential, but our stock price history suggests that this is indeed, how many investors look at us. A knock-out announcement would still come in handy, and one that carries financial weight.

https://seekingalpha.com/article/4419082-agex-therapeutics-new-lygensis-merger-may-unlock-much-needed-value

[saxonia40271]

I can’t say, I‘m the least bit surprised about today. This morning, it already looked like the market was completely unimpressed, and the stock fell, perhaps because the chart was already suggesting a re-test of the previous turning point. There‘s method to what we’re seeing here. The supercentenarian paper didn’t cut it either, nor did the news about the BAT study. What all of these events have in common, is that they don’t represent a tangible path to profitability, especially no timeframe. As I speculated in one of my previous posts, many factors might coincide here, and continue to keep the stock down. I‘d say, it‘s mostly the early-stage work, combined with funding needs, plus possibly a technology that is too mind-blowing to be understood, much less believed. On the other hand, we‘ve seen, how far meaningless events can take us, if there‘s only sufficient momentum.

The silver lining to this could be that the chart is far from uneventful, if you look past the day-to-day disappointments. Nothing suggests that what happened in October, was a common gap, or it probably would have been closed, months ago. Instead, the floor moved up to 1.41, where the stock stabilized in November.

I also think, there is a substantial possibility that the market could suddenly start playing this game in the opposite direction. Instead of constantly missing the prospects, and making a case like „90% of all drugs don’t make it past phase I“, the market could just as easily start pricing the stock, like there is no limit to their potential. This process might have already begun, only it‘s happening in slow motion. Once people take for granted that no run in AgeX will ever last, they might suddenly realize that they completely missed that it‘s already changed.

In the absence of hard facts on the balance sheet, the market might continue to knock us around. But substantial income might have already been placed in a far more distant future than it could turn out to be.

I still consider this level interesting. The possibility of being outperformed in the near-term, is ubiquitous. Perhaps the greatest challenge is the required patience. If the first question asked, is how many days it will take, to triple, the broad public might continue to ignore the AgeX stock. But this also means that many of them will end up chasing, when there finally is a lift-off.

Another aspect might be the lack of analyst coverage. A company, this small, remains under many radars. And almost no one will even dare to make any projections. They, too, could end up chasing. I‘m pretty sure that once we hit 20, someone will make the bold prediction that we might also hit 40. But to realize that 2 was a lot more interesting, that must be too much to ask. When standard indicators don’t apply yet, it seems like hardly anyone is ready to make a prediction anyway.

[saxonia40271]

@Bob

The market runs its own affairs. The stock is obviously drawn to its recent turning point at 1.89. If they announced the exclusive licensing of their cancer applications, for an upfront of half a billion, the market would have no choice. But there is always some excuse. I suppose, if West introduced mice that can regrow eyes, ears and legs, and are expected to last 1,000 years, we’d drop to an all-time low. I wish I could load, but none of what I‘m trying to sell, is even trading today. And what I could sell, I don’t feel like selling.

[bobby2loaves]

Hi All, it's Bob from the Yahoo AGE message board setting up shop here in Investor's Hub. Peter, PAR75 and Felix - you all are welcome to DM me if you are set up over here. I've got an item I'd like to discuss with you.

[trendzone]

Retards shorting premarket will end up getting burned up after the open.

[Topgun21]

Yummy! AGE $AGE

[Jaythesaabguy]

We shall see. Tomorrow could get interesting.

[The Big Lebowski]

Great day of action! Held strong... next leg coming???

[Jaythesaabguy]

Pretty large buys rolling in.

[The Big Lebowski]

Agreed then back up we go! Low floater here with big money behind it!

[Executive Order]

Institutional investors make shorters
VERY NERVOUS.

Especially if they have a 50% stake.

They're covering now. IMO

There could be a huge squeeze here.

ExOr

[The Big Lebowski]

Half the float locked up by institutional investors here. See where she goes.

[Jaythesaabguy]

Grabbed more at the bottom today!

[otcmoneydoubler]

AGE THIN ASK TO $6 AND 50% OF SHARES HELD BY INSTITUTION.

[ClayTrader]

* * $AGE Video Chart 10-08-2020 * *

Link to Video - click here to watch the technical chart video

[Good Timer]

Thank you Crudeoil24.

Juvenescence Limited must be highly regarded in the industry.

[crudeoil24]

AgeX Therapeutics shares are trading higher following an amended 13D filing showing Juvenescence Limited has a 50% stake in the company.

AGE

[doogdilinger]

As far as this massive dol vol wants to take it until news flow hits glta

[doogdilinger]

Someone in the great white north texted his buddies that they just struck a great vein!

Just joking!

But clearly someone knows something right glty!

[doogdilinger]

Best of cont'd success to all here! Been some excellent monsters like this one dating all the way back to KODK which has been an awesome addition to the HOT OTC casino we've had for most of this year!

[Good Timer]

Does anybody have an idea why the huge volume and price spikes with AGE today?

[PiecesOvEight]

to the moon

[doogdilinger]

Keep on banking Pedro! We got trade em not marry em when they're awakenin' hotties right cheers>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

[ronjon41]

How far can this run?

[Pedro2004]

I was in at $2.50 -- I got scared -- and I sold at $3.00

Looking for another entry

[Pedro2004]

watching

[doogdilinger]

ALL ABOARD!!!

[doogdilinger]

MA$$IVE big boy vol pouring in folks!!!

[doogdilinger]

KABOOM!!!

[doogdilinger]

Insane in the membrane weeeeeeeeeeeeeeeeeee

[otcmoneydoubler]

AGE ASK THIN ALL THE WAY TO $5.

[TheFinalCD]

what in the heck happened?

[ClayTrader]

* * $AGE Video Chart 05-29-2020 * *

Link to Video - click here to watch the technical chart video

[edwardport]

expect sell-off to .50